Can we prevent or treat multiple sclerosis by individualised vitamin D supply?
© Dörr et al. 2013
Received: 30 November 2012
Accepted: 9 January 2013
Published: 29 January 2013
Skip to main content
© Dörr et al. 2013
Received: 30 November 2012
Accepted: 9 January 2013
Published: 29 January 2013
Apart from its principal role in bone metabolism and calcium homeostasis, vitamin D has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamin D in autoimmune diseases like multiple sclerosis (MS). Indeed, several lines of evidence including epidemiologic, preclinical, and clinical data suggest that reduced vitamin D levels and/or dysregulation of vitamin D homeostasis is a risk factor for the development of multiple sclerosis on the one hand, and that vitamin D serum levels are inversely associated with disease activity and progression on the other hand. However, these data are not undisputable, and many questions regarding the preventive and therapeutic capacity of vitamin D in multiple sclerosis remain to be answered. In particular, available clinical data derived from interventional trials using vitamin D supplementation as a therapeutic approach in MS are inconclusive and partly contradictory. In this review, we summarise and critically evaluate the existing data on the possible link between vitamin D and multiple sclerosis in light of the crucial question whether optimization of vitamin D status may impact the risk and/or the course of multiple sclerosis.
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system (CNS) in young adults in Western countries and often leads to early disability and retirement . Typical clinical manifestations are optic neuritis, central paralysis, sensory disturbances, and difficulties in coordination and balance, as well as cognitive dysfunction, fatigue, and sleep disorders [1–3]. The initial course is usually relapsing-remitting, but after several years, the disease tends to convert into a secondary progressive form. A primary progressive course also exists but is much less common. It is estimated that 2.5 million people suffer from MS worldwide, and as in most autoimmune disorders, there is an obvious female preponderance of approximately 3 to 4:1 [1, 4]. Importantly, most female patients are affected in their child-bearing age which may have fundamental consequences for family planning . The cause of MS is not yet clear. Several genetic and environmental factors have been isolated to contribute to the risk of MS, among them vitamin D (VD) status, but the individual significance of each factor is not yet clear [6–10]. From the pathophysiological point of view, dysregulated encephalitogenic T cells are thought to initiate and to orchestrate in concert with abundant other immune cells an autoimmune multifocal CNS inflammation [11–13]. For decades, MS was considered to be a primarily demyelinating disorder predominantly affecting the CNS white matter. During recent years, however, it has become clear that MS also has a strong neurodegenerative component, which is most probably the underlying basis for the development of permanent disability [14–17]. Moreover, grey matter involvement has been increasingly recognised by means of histopathology and magnetic resonance imaging (MRI) [18–20]. Paraclinical tools for diagnosis, differential diagnosis, and monitoring of disease activity and progression in MS comprise cerebrospinal fluid examination, evoked potentials, MRI, and recently, optical coherence tomography [1, 21–24].
Current treatment concepts comprise the application of immunomodulatory or immunosuppressive drugs such as interferon-beta, glatiramer acetate, fingolimod, natalizumab, or mitoxantrone [25, 26]. Approval of additional new drugs is expected. However, most if not all of these drugs lack convincing neuroprotective capacity. Moreover, a substantial number of patients do not respond satisfyingly to these drugs or experience severe side effects [27–31]. Overall, there is still a need for improved therapeutic approaches, especially in neuroprotective substances .
Research on VD started around 1915, stimulated by the quest for an effective treatment of rickets. By the end of the 19th century, up to 90% of the children living in large cities throughout Northern Europe and the United States suffered from rickets, and the most common cause was the insufficient supply of VD due to low sun exposure as a side effect of increasing industrialisation. The transformation to an industrialised economy radically changed the living conditions for large parts of the population. Children often had to work many hours a day in factories or mines, being completely shielded from the sun. When VD deficiency was recognised as the main cause of rickets, a significant reduction of cases was achieved by preventive measures like radiation from ultraviolet lamps, greater amount of time spent outdoors, or fortification of food with VD .
Dietary sources of vitamin D
Vitamin D content (μg/100g)
Required daily intake (in g) for 20 μg vitamin D
Cod liver oil
Both VD2 and VD3 are biologically inactive. After intradermal synthesis or intestinal uptake, VD2 and VD3 are bound mainly to vitamin-D-binding-protein and transported to the liver, where they are enzymatically hydroxylated to 25(OH)VD (calcidiol). As this step is not tightly regulated and because of the relatively long half-life, serum levels of 25(OH)VD integrate both the endogenous and exogenous supply and provide a good estimate of an organism's VD status. The enzyme 1α-hydroxylase (CYP27B1), which is located mainly in the kidneys but also in other tissues, converts 25(OH)VD in a second hydroxylation step into the biologically active 1,25 dihydroxyvitamin D (1,25(OH)2VD; calcitriol) . Unlike the first hydroxylation, this second step is tightly regulated, among others by parathormone and calcium/phosphate levels . Calcitriol effects are mainly mediated via the intracellular VD receptor (VDR) which functions as a transcription factor and controls the expression of numerous genes. In its membrane-bound form, VDR mediates additional non-genomic functions including several signal transduction pathways [39, 40].
An ongoing debate addresses the optimal serum levels of 25(OH)VD. Currently, most experts consider 25(OH)VD levels above 30 ng/ml (75 nmol/l) as adequate [41–43], which is supported by the observations that serum levels of parathormone start plateauing at serum 25(OH)VD of 30 to 40 ng/ml and that immunological effects need serum levels around 30 ng/ml [35, 44]. Levels below 20 ng/ml (50 nmol/l) are considered deficient. Less clear are the upper limits since substantial variability occurs in naturally occurring 25(OH)VD levels. According to the literature, levels of up to 150 to 200 ng/ml (375 to 500 nmol/l) can be considered safe . Against this background, a significant proportion of the human population worldwide shows an alarming VD inadequacy [35, 44–46].
Since VD homeostasis is linked on multiple levels to the risk of not only various diseases such as cancer and autoimmune diseases, but also metabolic, cardiovascular, and psychiatric disorders [35, 42, 47, 48], the question arises whether improvement of VD supply may prevent or even treat respective diseases. Indeed, recent estimations indicate that yearly, >110,000 deaths could be prevented by adequate VD supply .
The presence of 1α-hydroxylase activity in neurons and microglia, and the presence of VD receptor in the CNS suggest local-, paracrine-, or autocrine-mediated effects of VD in the CNS [63, 64]. Interestingly, data from in vitro or animal studies suggest that neurotrophic factors such as nerve growth factor, neurotrophin 3, and glial cell line-derived neurotrophic factor are regulated by VD which might indicate additional, possibly neuroprotective effects of VD . Whether VD has clinically relevant neuroprotective properties still remains a subject of discussion.
It is long known that genetic factors contribute to the risk of MS. In particular, an association with extended major histocompatibility complex haplotypes, especially those containing HLA-DRB1*1501, has been consistently shown in individuals of northern European ancestry [66, 67]. The role of VD-related genes in determining MS risk or specific genetic interactions with VD is currently a hot focus of research and is not yet completely understood. So far, two interesting links merit mentioning: First, it was recently shown that the gene expression of allele HLA-DRB1*1501 is modulated by VD, and a highly conserved VD-responsive element has been identified in the promoter region of the HLA-DRB1*1501 haplotype, which may indicate a direct functional interaction between VD and the major locus determining genetic susceptibility to MS . Second, loss of function variants in the CYP27B1 gene which encodes the enzyme that converts 25(OH)VD into its active form were shown to be associated with an increased MS risk . In the same direction points a possible association between MS and VD-dependent rickets type I, which is a rare hereditary condition caused by a mutation in CYP27B1[70, 71].
Further evidence for a causal relation between VD supply and both development and treatment of MS were derived from experimental autoimmune encephalomyelitis (EAE), the best established rodent animal model for MS. In murine EAE, prophylactic application of VD (starting at disease induction) resulted in a reduction of both disease incidence and severity. Likewise, the therapeutic VD application (starting at onset of symptoms) lead to a significant reduction of disease severity [72–74]. Interestingly, some studies suggested gender-specific efficacy of VD only in female mice . In a recent study, continuous treatment of mice with UVR dramatically suppressed clinical signs of EAE. Interestingly, the therapeutic effect was paralleled by only a moderate and transient increase of serum 25(OH)VD levels, which suggests that directly UVR-mediated effects which were at least partly independent of VD contributed to this observation . In another recent study using the cuprizone model, dietary VD could (partly) prevent chemically induced CNS demyelination in mice .
First hypotheses on a possible link between MS risk and VD deficiency were derived from the observation that the risk of MS is associated with latitude [78, 79] which in turn shows a strong inverse correlation with UVB exposure. Furthermore, migrating from high to low latitude appears to reduce the MS risk . This link was further corroborated by the observation of a MS risk lower than one would expect from the latitude in regions with a high consume of fatty VD-rich fish . More recent investigations, however, suggest that this latitude gradient is fading which might be explained by several possible reasons, including better MS recognition, changes in lifestyle, and improvement of sanitary circumstances . More indirect though not unambiguous support for a beneficial effect of VD comes from the observation that both MS risk and disease activity show a seasonal association. As shown in several studies including a very recent meta-analysis, humans born in spring have a significant higher risk to develop MS later in life than people born in autumn [82–85] which might be at least partially explained by longer in utero VD insufficiency due to lower motherly VD levels in winter/spring as compared to summer/autumn. Likewise, several methodically high quality studies showed an inverse association between sun exposure or outdoor activities during childhood and adolescence, and the risk of developing MS during adulthood [86–90]. In line with these reports is the recent observation that low sun exposure in fall/winter before disease onset was associated with a less favourable outcome . Yet, all these studies have two major intrinsic limitations: first, despite a reported reasonable validity and reliability , the retrospective determination of sun exposure years or even decades in the past is inevitably subjected to recall bias , and prospective studies are hardly available. The determination of actinic damage as a surrogate parameter for cumulative sun exposition might be a viable loophole [34, 86]. Second, sun exposure itself may have intrinsic immunomodulatory effects, independent of VD [76, 93, 94]. Also, not easy to harmonise with sun exposure or VD synthesis is the seasonal dependency of disease activity in already established MS. Several studies including a meta-analysis showed an excess of clinical exacerbations and MRI activity in spring/summer and a nadir in autumn/winter in the northern hemisphere [95–98]. Correspondingly, a reverse situation was observed in the southern hemisphere . While a peak of disease activity in spring and a nadir in autumn in the northern hemisphere could be explained with a few-month lag in the course of serum VD levels, the situation in summer and winter does not easily fit with a protective role of VD. In conclusion, VD might contribute to some but cannot sufficiently explain all geographic and seasonal associations observed in MS.
The rather indirect impact of predictors of 25(OH)VD levels on MS has been discussed above. But, how does the 25(OH)VD serum level itself sway the risk and course of MS? Generally, if VD had a beneficial effect on MS risk, one would demand an inverse relation between VD intake or serum levels and MS incidence. Indeed, various studies demonstrated such a relation. Most data on this issue, however, are derived from epidemiologic or observational studies, meaning, that methodical limitations like selection bias, retrospective survey, and interference with various confounders should be kept in mind. One recent study suggests that already in utero levels of VD, which are completely dependent on the mother's VD status, impact the risk to develop MS later in life . In a Canadian cohort study on children presenting with a first demyelinating event, the risk to develop definite MS within the following 3 years was inversely and independently correlated with the 25(OH)VD serum level . Furthermore, data from a nested case–control study involving more than seven million individuals of the US military suggest that in healthy young white adults, higher 25(OH)VD levels are predictive of a significantly lower risk of developing MS (62% lower odds in the top quintile of 25(OH)VD serum levels compared to the bottom quintile), independent from latitude of residency in childhood . Another study by the same group addressed the relation between VD intake and MS risk in a cohort of approximately 200,000 US women and reported a 33% reduction of MS incidence over a follow-up period of 30 years when comparing the top quintile and the bottom quintile of VD intake. Moreover, in women taking daily supplements containing at least 400 IU VD, a 41% lower MS incidence was observed when compared to women who did not take supplements . Likewise, in another survey, intake of cod liver oil was associated with a 4-year delay of MS onset . In summary, substantial evidence exists for an inverse association between VD and the risk of developing MS.
But, how does the situation look in already established MS? A number of studies consistently suggest that higher VD serum levels are associated with a more favourable disease course. In a small Finnish study, lower summer 25(OH)VD concentrations were measured in patients with a first MS relapse compared to healthy controls, and 25(OH)VD concentrations were significantly lower during relapses than in remission phases which may point to a regulative role of VD for MS activity . Compelling support for this hypothesis comes from four independent recent reports, all showing a close relationship between clinical disease activity and 25(OH)VD concentrations: Two studies demonstrated that every 10 nmol/l increase of the VD serum level is correlated with a reduction of relapse occurrence of 11% and 13.7%, respectively [105, 106]. A third study demonstrated a log linear association between serum VD concentration and MS relapse rate in that every doubling of serum levels reduced relapse rate by 27% . The fourth study finally revealed a 34% reduction of relapse rate by every 10 ng/ml increase in paediatric onset MS . In line with these clinical data, an inverse association between VD concentrations and disease activity on cranial MRI was recently demonstrated, but may possibly be restricted to patients without additional immunomodulatory treatment [109, 110]. Of note, in studies addressing the relation between clinical disease activity and VD levels, a reverse association (low VD concentrations as a consequence rather than a cause of a relapse) cannot be completely ruled out. In contrast to the serum concentrations, a statistical difference in cerebrospinal fluid VD levels was neither observed between MS patients and healthy controls or in MS patients between phases of disease activity or in remission .
In conclusion, cumulating evidence quite consistently argues for a relationship between VD status and both risk and activity of MS. Of note, however, all these studies are methodically prone to bias and are therefore not suited to definitely proof such a relation.
The compelling evidence for the beneficial impact of higher VD serum concentrations on disease activity leads directly to two questions: (a) do patients with already established MS benefit from a therapeutic elevation of their VD levels and (b) if so, which 25(OH)VD serum levels should be strived for in MS patients? To reliably answer these crucial questions, high quality and sufficiently powered interventional trials are required. Moreover, important issues like optimal dosing schemes need further clarification. So far, there are only few prospective clinical studies on VD as a treatment for MS, some of them of rather questionable quality. An early uncontrolled study involving 16 MS patients (evidence level IIb) showed that regular intake of cod liver oil (equivalent to 5,000 IU VD/day) for a period of up to 2 years lead to a lower relapse rate as would have been expected from the participants' medical histories . From today's point of view, design and sample size of this study are however not appropriate to address a therapeutic effect of VD. Another small and uncontrolled study with a primary focus on safety aspects (evidence level IIb) provided evidence that escalating VD doses up to 280,000 IU/week over a rather short period of 28 weeks are safe in MS patients. No significant effects on clinical parameters were observed, but there was a possible effect on MRI activity . In a successive randomised controlled but open label study, the same group applied cholecalciferol (up to 40,000 or 4,000 IU/d) continuously for 52 weeks in 49 MS patients (evidence level Ib). Patients in the high dose arm showed a significant reduction of the annualised relapse rate . In another randomised double blind and placebo-controlled study focusing on serological markers of disease activity (evidence level IIb), administration of 1,000 IE cholecalciferol for a period of 6 months lead to a significant increase of the anti-inflammatory cytokine transforming growth factor-β and to a partial reduction of the IL-2 level . Another recent study (evidence level IIb) reported no significant differences between the high- or low-dose ergocalciferol on clinical and MRI parameters . However, the design of this study (small number, inhomogeneous group of patients, short period of observation, relatively high dosages of “low-dose” ergocalciferol) has been criticised as not being suited to address the therapeutic capacity of VD in MS . The capacity of low dose calcitriol to prevent disease progression in relapsing remitting multiple sclerosis (RRMS) when given in adjunction to undefined disease-modifying treatment strategies was investigated in a randomised and double blind but rather small study on 50 patients. After 12 months, no significant differences between verum and placebo arms were observed with respect to relapse rate and disability . Two recently published studies from Finland and Norway, both applying 20,000 IU/week in a randomised, double blind and placebo-controlled design (evidence level Ib), yielded partly contradictory results with respect to clinical and MRI parameters. In the Finish study, mean 25(OH)VD serum levels in patients receiving VD over 1 year in addition to IFN-β increased to 110 nmol/l, and patients in the verum group showed significantly fewer gadolinium-enhancing lesions and a tendency to reduced disability accumulation and improved ambulation parameters. The annualised relapse rate was not different in both arms . In an active subgroup of this study, an additional beneficial effect of VD on new/enlarging T2 hyperintense brain lesions was observed . In the 96-week Norwegian trial, no significant differences were observed in annualised relapse rate, EDSS, MSFC, grip strength, or fatigue although the median 25(OH)VD serum concentration in the verum group raised to 121 nmol/l .
Ongoing clinical trials on vitamin D in multiple sclerosis (registered at http://www.clinicaltrials.gov by January 2013)
Trial title/registration number
Start date/estimated completion date
Number of participants
Main outcome parameters
Phase II study of efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS study)
Charité-Universitätsmedizin Berlin, Germany
December 2011/March 2015
Cholecalciferol 20,400 IU every other day (high dose) or cholecalciferol 400 IU/every other day (low dose) for 18 months
Randomised double blind active controlled multicenter Phase II trial
80 patients with RRMS or CIS
Primary: cumulative number of new T2 lesions
Add-on to IFN β1b 250 μg every other day
Secondary: annualised relapse rate, occurrence of disability progression, proportion of patients without disease activity, conversion rate into definite MS, cumulative number of T1 gadolinium-enhancing lesion, number and volume of new T1 hypointense lesions, number and volume of new T2 hyperintense lesions, changes in brain parenchymal volume, changes in magnet resonance spectroscopy, changes in retinal structure as determined by optical coherence tomography, changes in cognitive function and fatigue, change in health-related quality of life
Supplementation of VigantOL® oil versus placebo as add-on in patients with relapsing remitting multiple sclerosis receiving Rebif® treatment (SOLAR study)
February 2011/ March 2014
Cholecalciferol 14,000 IU/day or placebo for 96 weeks
Randomised double blind placebo-controlled multicenter phase II trial
348 patients with RRMS
Primary: mean number of active lesions at week, proportion of relapse-free subjects
Add-on to IFN β1a 44 μg 3×/week
Secondary: annualised relapse rate, proportion of subjects free from any EDSS progression, proportion of subjects free from disease activity, change in cognitive function, cumulative number of T1 gadolinium enhancing lesion, proportion of subjects free from new T1 hypointense lesions, change from baseline in the total volume of T2 lesions, percent brain volume change with respect to baseline
A multicentre, randomised, double-blind, placebo-controlled study of the efficacy of supplementary treatment with cholecalciferol in patients with relapsing multiple sclerosis treated with subcutaneous IFN Beta-1a 44 μg 3 times weekly
January 2010/July 2014
Cholecalciferol 2× 100,000 IU/month or placebo for 96 weeks
Randomised double blind placebo-controlled multicenter phase II trial
250 patients with RRMS
Primary: reduction of relapse rate
Add-on to IFN β1a 44 μg 3×/week
Secondary: number of relapse-free subjects, cumulative probability of progression of disability, number of new or extended lesions in T1- and T2-weighted MRI, changes in lesion load (T2), number of new lesions (T1 gadolinium activity and black holes), measurement and evaluation of cognitive ability, change in quality of life, safety of the treatment
A pilot study to assess the relative safety and immunology effects of low dose versus high dose cholecalciferol supplementation in patients with multiple sclerosis
Johns Hopkins University, Baltimore, USA
March 2010/December 2011
Cholecalciferol 10,000 IU/day (high dose) or cholecalciferol 400 IU/day (low dose) for 6 months
Randomised double blind controlled multicenter phase II trial
40 MS patients with or without immunomodulatory treatment and serum 25(OH)VD levels between 20–50 ng/ml
Primary: safety of high-dose cholecalciferol, effects of cholecalciferol supplementation on serum immune markers
Secondary: clinical effects of cholecalciferol supplementation
A randomised controlled trial of vitamin D supplementation in multiple sclerosis
Johns Hopkins University, Baltimore, USA
March 2012/December 2014
Cholecalciferol 5,000 IU/day (high dose) or cholecalciferol 600 IU/day (low dose) for 24 months
Randomised double blind controlled multicenter phase III trial
172 RRMS patients with 25(OH)D-serum levels ≥ 15 ng/ml
Primary: proportion of subjects that experience a relapse
Add-on to glatiramer acetate 20 mg/day
Secondary: annualised relapse rate, occurrence of sustained disability progression, number of new T2 lesions, changes in brain parenchymal volume and cortical thickness, change in low-contrast visual acuity, change in health-related quality of life, development of hypercalcemia/related adverse effects
Pharmacodynamic and immunologic effects of vitamin D supplementation in patients with multiple sclerosis and healthy controls
Johns Hopkins University, Baltimore, USA
November 2010/June 2013
Cholecalciferol 5,000 IU/day for 90 days
Non-randomised, open label single group assignment multicenter phase 1 trial
60 patients with RRMS or healthy individuals
Primary: change in mean serum level of 25(OH)VD
Secondary: cytokine levels and percentages of T and B cells, gene expression microarray
Role of vitamin D on the relapse rate of multiple sclerosis
AlJohara M AlQuaiz, M.D., King Saud University, Saudi Arabia
January 2013/October 2014
Cholecalciferol 50,000 IU/week or placebo for 12 months
Randomised double blind controlled single centre phase II trial
200 patients with RRMS
Primary: relapse rate
Secondary: improvement in the EDSS score
Dose-related effects of vitamin D3 on immune responses in patients with clinically isolated syndrome and healthy control participants. An exploratory double blind placebo randomised controlled study
University College Dublin, Ireland
November 2012/May 2014
Cholecalciferol 5,000 IU/day or 10,000 IU/day or placebo for 24 weeks
Randomised double blind placebo-controlled phase II trial
45 patients with CIS without any immunomodulatory treatment and 39 healthy individuals
Primary: change in the frequency of CD4 T cell subsets and cytokine responses of periphery blood mononuclear cells
Secondary: relapse occurrence, percentage of CIS patients in each treatment arm free from any evidence of disease activity, number of new T2 and gadolinium-enhancing lesions
With respect to safety, more clinical data already exist. Generally, (iatrogenic) VD excess can result in life-threatening hypercalcaemia and has been occasionally reported on the basis of single cases . However, unlike supplementation with high dose calcitriol, which indeed seems to bear a significant risk of symptomatic hypercalcaemia , treatment of MS patients with even very high doses of cholecalciferol or ergocalciferol was repeatedly demonstrated to be safe [113, 114, 116, 119, 121]. While a Cochrane report published in 2010 concludes that available data are not yet sufficient to draw the right conclusions regarding safety of VD supplementation , another recent meta-analysis suggests that daily doses of 10,000 IE cholecalciferol can be considered safe .
In this review article, which follows the recommendations of the “EPMA White Paper” , we summarise and discuss available data on the role of VD for the development and disease course of MS. Many lines of evidence, in particular epidemiologic data, preclinical investigations, animal studies, and association studies on VD status and disease activity, suggest that higher serum concentrations of VD are beneficial in terms of the risk to develop MS as well as the further course of the disease in already-established MS. Moreover, VD supplementation is safe, cheap, and convenient to perform. Therefore, it is intriguing to hypothesise that boosting the VD serum levels would be an option to both prevent and treat MS. Despite the inherent methodological drawbacks of epidemiologic studies, existing data on the preventive capacity of higher VD levels are quite compelling. Final proof of this hypothesis would be reached by large-scale prospective epidemiological studies which will probably not be available in the near future, for obvious reasons. With respect to the therapeutic efficacy, an association between higher VD serum concentrations and a favourable disease course has been conclusively shown. Unfortunately, the so-far performed interventional trials, though not negotiating this hypothesis, also do not unambiguously support the idea that raising patients' VD levels would be favourably in terms of disease outcome. Hopefully, ongoing (Table 2) and future trials will shed more light on this aspect.
But, how are we going to deal with this issue in the meantime? From a pragmatical point of view and considering available data on efficacy, safety, tolerability, and last but not least costs, it seems to be reasonable to regularly control 25(OH)VD levels in MS patients, especially during winter months. In patients with inadequate VD, levels should be raised to at least 30–40 ng/ml (75–100 mmol/l), either by appropriate sun exposure and/or adequate VD supplementation. As a rule of thumb, supplementary 1 μg (40 IU) cholecalciferol will increase 25(OH)VD levels by 1 ng/ml (2.5 nmol/l).
JD is a neurologist and a senior physician/scientist at the NeuroCure Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Germany, and has a research focus on the role of VD in MS. As head of the NCRC Neuroimmunological Study Outpatient Department, he is currently running a therapeutic phase II clinical trial on VD in MS. AD is a physician; she completed part of her neurological training at the NCRC. FP is a senior neurologist and head of the Neuroimmunological Group at the NCRC. His research focus is the translation of new diagnostic tools and therapeutic approaches in MS and related disorders into the clinical setting.
This work was supported by the DFG (Exc 257).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.